{"id":"sirolimus-mycophenolat-mofetil-fluvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1456","moleculeType":"Small molecule","molecularWeight":"433.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sirolimus inhibits mTOR signaling to suppress T-cell and B-cell proliferation. Mycophenolat mofetil inhibits IMPDH to selectively deplete guanosine nucleotides in lymphocytes. Fluvastatin reduces cholesterol synthesis and has pleiotropic immunomodulatory effects. Together, this combination provides potent immunosuppression with cardiovascular protection.","oneSentence":"This is a triple immunosuppressive and lipid-lowering regimen combining mTOR inhibition, inosine monophosphate dehydrogenase inhibition, and HMG-CoA reductase inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:17.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis"},{"name":"Cardiovascular risk reduction in transplant recipients"}]},"trialDetails":[{"nctId":"NCT00223028","phase":"PHASE4","title":"Investigation of the Steady State Pharmacokinetics of Sirolimus, Mycophenolat Mofetil and Fluvastatin After Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital Schleswig-Holstein","startDate":"2005-04","conditions":"Renal Transplantation","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sirolimus, mycophenolat mofetil, fluvastatin","genericName":"sirolimus, mycophenolat mofetil, fluvastatin","companyName":"University Hospital Schleswig-Holstein","companyId":"university-hospital-schleswig-holstein","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a triple immunosuppressive and lipid-lowering regimen combining mTOR inhibition, inosine monophosphate dehydrogenase inhibition, and HMG-CoA reductase inhibition. Used for Organ transplant rejection prophylaxis, Cardiovascular risk reduction in transplant recipients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}